Literature DB >> 16316454

Biological activities of cecropin B-thanatin hybrid peptides.

W Hongbiao1, N Baolong, X Mengkui, H Lihua, S Weifeng, M Zhiqi.   

Abstract

Ten kinds of hybrid peptides containing the N-terminal residues of cecropin B (CB) and C-terminal of thanatin (TH) were constructed and expressed as gluthathion S-transferase (GST)-fusion proteins. Variants were screened for the better biological activity, which was paralleled with the degree of growth inhibition of the transformant cells. The hybrid CB-TH g was selected as the best one among those hybrids by in vivo monitoring method and was chemical synthesized for in vitro antimicrobial activity analysis. The hybrid peptide showed rescued activity against several test strains when compared with the truncated isoforms of TH, suggesting that the peptides with different structure and mechanism could be used as templates for hybrid peptides design.

Mesh:

Substances:

Year:  2005        PMID: 16316454     DOI: 10.1111/j.1399-3011.2005.00299.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  4 in total

1.  Enhanced antibacterial activity of an attacin-coleoptericin hybrid protein fused with a helical linker.

Authors:  Minsup Lee; Kyeongrin Bang; Hyojung Kwon; Saeyoull Cho
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

2.  Hybrids made from antimicrobial peptides with different mechanisms of action show enhanced membrane permeabilization.

Authors:  Heidi M Wade; Louise E O Darling; Donald E Elmore
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-05-05       Impact factor: 3.747

3.  Fusion proteins towards fungi and bacteria in plant protection.

Authors:  Ana Margarida Pinheiro; Alexandra Carreira; Ricardo B Ferreira; Sara Monteiro
Journal:  Microbiology       Date:  2017-12-14       Impact factor: 2.777

Review 4.  Thanatin: An Emerging Host Defense Antimicrobial Peptide with Multiple Modes of Action.

Authors:  Rachita Dash; Surajit Bhattacharjya
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.